Download Files:
GRL0617
$90 – $670
Products Details
Product Description
– GRL0617 is a selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLpro), with an IC50 of 0.6 μM and a Ki value of 0.49 μM. GRL0617 also inhibits SARS-CoV with an EC50 of 14.5 μM. GRL0617 can be used for the research of severe acute respiratory syndrome[1].
Web ID
– HY-117043
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C20H20N2O
References
– [1]Ratia K, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16119-24.
CAS Number
– 1093070-16-6
Molecular Weight
– 304.39
Compound Purity
– 99.71
SMILES
– O=C(N[C@@H](C1=C2C=CC=CC2=CC=C1)C)C3=CC(N)=CC=C3C
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– DMSO : 125 mg/mL (ultrasonic)
Target
– Deubiquitinase;SARS-CoV
Pathway
– Anti-infection;Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
